title: Candesartan cilexetil: a review of its use in the management of chronic heart failure.
abstract: Candesartan cilexetil is the orally administered pro-drug of candesartan, a highly selective antagonist of the angiotensin II subtype 1 receptor that mediates the pressor activities of angiotensin II. Candesartan cilexetil is widely used for the treatment of hypertension and has recently been approved in Europe for the treatment of chronic heart failure (CHF) in patients with impaired left ventricular (LV) systolic function. Results of the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) programme suggest that oral candesartan cilexetil reduces morbidity and mortality in patients with CHF and LV ejection fraction (LVEF) < or =40%. There are cardiovascular benefits when candesartan cilexetil is administered as an alternative to an ACE inhibitor, or as an add-on to current treatment regimens that include an ACE inhibitor, in symptomatic CHF. While tolerability is generally good, renal monitoring is required. The recent approval of candesartan cilexetil as both add-on and alternative therapy to ACE inhibitors in patients with CHF and impaired LV systolic function recognises the cardiovascular benefits of candesartan cilexetil in both types of treatment regimens.
authors.affiliation: Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand. demail@adis.co.nz
authors.forename: Caroline
authors.initials: C
authors.lastname: Fenton
authors.forename: Lesley J
authors.initials: LJ
authors.lastname: Scott
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology*; D001713:Biphenyl Compounds / Q000494:pharmacology*; D002908:Chronic Disease; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D013777:Tetrazoles / Q000494:pharmacology*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; C077793:candesartan cilexetil
references.citation: Heart. 2002 Oct;88 Suppl 2:ii40-6
references.pmid: 12213800
references.citation: Circulation. 2004 Oct 26;110(17):2618-26
references.pmid: 15492298
references.citation: Eur Heart J. 2001 Sep;22(17):1527-60
references.pmid: 11492984
references.citation: N Engl J Med. 2003 Nov 13;349(20):1893-906
references.pmid: 14610160
references.citation: Eur J Heart Fail. 2003 Oct;5(5):669-77
references.pmid: 14607207
references.citation: Can J Cardiol. 1997 Dec;13(12):1166-74
references.pmid: 9444298
references.citation: Ann Intern Med. 2004 Jul 20;141(2):102-12
references.pmid: 15262665
references.citation: Circulation. 1992 Feb;85(2):790-804
references.pmid: 1370925
references.citation: J Am Coll Cardiol. 2004 Nov 2;44(9):1841-6
references.pmid: 15519017
references.citation: Can J Cardiol. 2003 Mar 31;19(4):347-56
references.pmid: 12704478
references.citation: Lancet. 2003 Sep 6;362(9386):777-81
references.pmid: 13678871
references.citation: J Am Coll Cardiol. 2001 Dec;38(7):2101-13
references.pmid: 11738322
references.citation: Drugs. 2002;62(10):1433-40
references.pmid: 12093312
references.citation: Am J Health Syst Pharm. 2004 May 1;61 Suppl 2:S4-13
references.pmid: 15160833
references.citation: J Hum Hypertens. 1997 Sep;11 Suppl 2:S37-42
references.pmid: 9331004
references.citation: Clin Drug Investig. 2003;23(8):545-50
references.pmid: 17535067
references.citation: Clin Pharmacokinet. 2002;41(1):7-17
references.pmid: 11825094
references.citation: N Engl J Med. 1996 Jun 20;334(25):1649-54
references.pmid: 8628362
references.citation: J Hum Hypertens. 2002 Aug;16 Suppl 3:S9-S16
references.pmid: 12140723
references.citation: Drugs. 2002;62(8):1253-87
references.pmid: 12010090
references.citation: Eur Heart J. 2004 Mar;25(5):357-8
references.pmid: 15033244
references.citation: Eur Heart J. 2004 Nov;25(21):1920-6
references.pmid: 15522471
references.citation: Lancet. 2003 Sep 6;362(9386):759-66
references.pmid: 13678868
references.citation: Ethn Dis. 2002 Winter;12(1):S1-3-11
references.pmid: 11913616
references.citation: Lancet. 2003 Jul 5;362(9377):7-13
references.pmid: 12853193
references.citation: Circulation. 2002 Apr 30;105(17):2099-106
references.pmid: 11980691
references.citation: J Hum Hypertens. 1997 Sep;11 Suppl 2:S31-5
references.pmid: 9331003
references.citation: J Am Coll Cardiol. 2002 Jan 2;39(1):79-82
references.pmid: 11755290
references.citation: J Hypertens. 2001 Oct;19(10):1905-12
references.pmid: 11593113
references.citation: Circulation. 1999 Nov 30;100(22):2224-30
references.pmid: 10577995
references.citation: Lancet. 2003 Sep 6;362(9386):767-71
references.pmid: 13678869
references.citation: Drugs. 2002;62(5):787-816
references.pmid: 11929332
references.citation: Circulation. 1999 Sep 7;100(10):1056-64
references.pmid: 10477530
references.citation: Drugs. 1998 Nov;56(5):847-69
references.pmid: 9829158
references.citation: Am Heart J. 2003 Mar;145(3):E14
references.pmid: 12660683
references.citation: Am J Hypertens. 2002 Nov;15(11):1006-14
references.pmid: 12441224
references.citation: J Hum Hypertens. 1997 Sep;11 Suppl 2:S19-25
references.pmid: 9331000
references.citation: Eur J Heart Fail. 2003 Jun;5(3):261-70
references.pmid: 12798823
references.citation: Circulation. 1998 Jul 7;98(1):73-81
references.pmid: 9665063
references.citation: Lancet. 2003 Sep 6;362(9386):772-6
references.pmid: 13678870
references.citation: N Engl J Med. 2001 Dec 6;345(23):1667-75
references.pmid: 11759645
references.citation: Hypertension. 1995 Jan;25(1):14-21
references.pmid: 7843746
references.citation: Eur J Clin Pharmacol. 1999 Feb;54(12):953-8
references.pmid: 10192757
references.citation: Eur Heart J. 2003 Oct;24(19):1727-34
references.pmid: 14522567